We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure
Read MoreHide Full Article
Insulet Corporation (PODD - Free Report) continues to gain on solid prospects in the diabetes market. A tough competitive landscape raises concerns. The stock carries a Zacks Rank #3 (Hold).
Over the past year, Insulet has been outperforming its industry. The stock has gained 47.7% compared with the industry’s 15.1% rise. Insulet exited the second quarter of 2021 with better-than-expected revenues. The year-over-year improvement in the top line on solid uptake of the Omnipod system, both in the United States and international markets, was encouraging.
The company’s second-quarter U.S. Omnipod revenues grew 16.8% year over year, meeting the low end of the guidance, driven by total Omnipod growth of 19.9% year over year. Clinical data demonstrating the efficacy of the Omnipod product platform looks compelling as well. Insulet’s plan to launch the Omnipod 5 buoys optimism for the stock. New customer starts registered record-high growth in the second quarter.
The company is gradually improving with respect to seamless supply chain and manufacturing operations. It has also added significant capacity in preparation for the Omnipod 5 launch in 2021.
For 2021, Insulet expects total Omnipod revenue growth in the range of 18% to 21%.Total company revenue growthis expectedin the band of 16% to 20% on strong volume growth of Omnipod DASH, aided by increased investment in awareness, a differentiated pay-as-you-go model in the pharmacy with a mix benefit, expanded access, and Omnipod adoption in the Type 1 and Type 2 diabetes market.
Insulet expects full-year gross margin in the band of 68% to 69%. This expansion will be driven by ongoing benefits of volume shift into the U.S. pharmacy channel, benefits from enhanced manufacturing operations,and lower COVID-related costs.
On the flip side, Insulet exited the second quarter of 2021 with lower-than-expected earnings. Adjusted earnings of 10 cents per share reflected a 54.5% decline from the year-ago earnings. Earnings also missed the Zacks Consensus Estimate by 16.7%. A year-over-year decline in gross profit does not bode well either.
The escalating expenses built pressure on the bottom line. In the second quarter of 2021, selling, general & administrative expenses rose 43.9%, while research and development expenses increased 17.3% year over year.
The projection of a significant fall in Drug Delivery sales in 2021 is concerning. Overall, the continued pandemic-led choppy market conditions raise apprehensions.
Image: Bigstock
Insulet (PODD) Gains on Omnipod Sales Amid Cost Pressure
Insulet Corporation (PODD - Free Report) continues to gain on solid prospects in the diabetes market. A tough competitive landscape raises concerns. The stock carries a Zacks Rank #3 (Hold).
Over the past year, Insulet has been outperforming its industry. The stock has gained 47.7% compared with the industry’s 15.1% rise. Insulet exited the second quarter of 2021 with better-than-expected revenues. The year-over-year improvement in the top line on solid uptake of the Omnipod system, both in the United States and international markets, was encouraging.
The company’s second-quarter U.S. Omnipod revenues grew 16.8% year over year, meeting the low end of the guidance, driven by total Omnipod growth of 19.9% year over year. Clinical data demonstrating the efficacy of the Omnipod product platform looks compelling as well. Insulet’s plan to launch the Omnipod 5 buoys optimism for the stock. New customer starts registered record-high growth in the second quarter.
The company is gradually improving with respect to seamless supply chain and manufacturing operations. It has also added significant capacity in preparation for the Omnipod 5 launch in 2021.
Insulet Corporation Price
Insulet Corporation price | Insulet Corporation Quote
For 2021, Insulet expects total Omnipod revenue growth in the range of 18% to 21%.Total company revenue growthis expectedin the band of 16% to 20% on strong volume growth of Omnipod DASH, aided by increased investment in awareness, a differentiated pay-as-you-go model in the pharmacy with a mix benefit, expanded access, and Omnipod adoption in the Type 1 and Type 2 diabetes market.
Insulet expects full-year gross margin in the band of 68% to 69%. This expansion will be driven by ongoing benefits of volume shift into the U.S. pharmacy channel, benefits from enhanced manufacturing operations,and lower COVID-related costs.
On the flip side, Insulet exited the second quarter of 2021 with lower-than-expected earnings. Adjusted earnings of 10 cents per share reflected a 54.5% decline from the year-ago earnings. Earnings also missed the Zacks Consensus Estimate by 16.7%. A year-over-year decline in gross profit does not bode well either.
The escalating expenses built pressure on the bottom line. In the second quarter of 2021, selling, general & administrative expenses rose 43.9%, while research and development expenses increased 17.3% year over year.
The projection of a significant fall in Drug Delivery sales in 2021 is concerning. Overall, the continued pandemic-led choppy market conditions raise apprehensions.
Key Picks
A few better-ranked stocks from the broader medical space include Intuitive Surgical, Inc. (ISRG - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) , and Envista Holdings Corporation (NVST - Free Report) , each carrying a Zacks Rank #2(Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Intuitive Surgical has a long-term earnings growth rate of 9.7%.
IDEXX has a long-term earnings growth rate of 19.9%.
Envista Holdings has a long-term earnings growth rate of 27.4%.